Newer pathologic assessment techniques for colorectal carcinoma

Clinical Cancer Research

Volumn 13, Issue 22, 2007, Pages

  Turner, Roderick R ^a,b   Li, Carolyn ^b   Compton, Carolyn C ^c  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b SAINT JOHN'S HEALTH CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ANGIOGENESIS; APOPTOSIS; CANCER GRADING; CELL ADHESION; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CHROMOSOME DELETION; COLORECTAL CARCINOMA; CONFERENCE PAPER; GENE EXPRESSION; GENETIC COUNSELING; GENOTYPE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE; MICROARRAY ANALYSIS; MICROSATELLITE INSTABILITY; ONCOGENE; PATHOGENESIS; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPH NODES; MICROSATELLITE INSTABILITY; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 36749036704     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1151     Document Type: Conference Paper

References (61)

1. Ahmed FE. Development of novel diagnostic and prognostic molecular markers for sporadic colon cancer. Expert Rev Mol Diagn 2005;5:337-52.
2. Ahmed FE. Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn 2005;5:353-75.
3. Fearon E, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-67.
4. Morin PJ, Vogelstein B, Kinzler KW. Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci U S A 1996;93:7950-4.
5. Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Path Lab Med 2000;124:979-94.
6. International Agency for Research on Cancer (IARC). Tumours of the colon and rectum. In: Hamilton SR, Aaltonen LA, editors. Pathology and genetics. Tumours of the digestive system. Lyon: IARC Press; 2000. p.110-1.
7. Purdie CA, Piris J. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. Histopathology 2000;36:121-6.
8. Redston M. Epithelial neoplasms of the large intestine. In: Odze RD, Goldblum JR, Crawford JM, editors. Surgical pathology of the GI tract, liver, biliary tract, and pancreas. Philadelphia: Elsevier; 2004. p. 447-8.
9. Morodomi T, Isomoto H, Shirouzu K, et al. An index for estimating the probability of lymph node metastasis in rectal cancers. Lymph node metastasis and the histopathology of actively invasive regions of cancer. Cancer 1989;63:539-43.
10. Kaihara T, Kusaka T, Nishi M, et al. Dedifferentiation and decreased expression of adhesion molecules, E-cadherin and ZO-1, in colorectal cancer are related to liver metastasis. J Exp Clin Cancer Res 2003;22:117-23.
11. Suzinska-Ustymowiczk K, Zalewski B, Kasacka I, et al. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer. Anticancer Res 2006;26:1589-94.
12. Tanaka M, Hashiguchi Y, Ueno H, et al. Tumor budding at the invasive margin can predict patients at high risk of recurrence after curative surgery for stage II, T3 colon cancer. Dis Colon Rectum 2003;46:1054-9.
13. Park K-J, Choi H-J, Roh M-S, et al. Intensity of tumor budding and its prognostic implications in invasive colon carcinoma. Dis Colon Rectum 2005;48:1597-602.
14. Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum 2003;46:1400-6.
15. Kazama S, Watanabe T, Ajioka Y, et al. Tumor budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM 5.2. Br J Cancer 2006;94:293-8.
16. Jass J, Atkin W, Cuzick J, et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases. Histopathology 1986;10:437-59.
17. Jass J, Love S, Northover J. A new prognostic classification of rectal cancer. Lancet 1987;1:1303-6.
18. Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor "budding" in patients with colorectal cancer. Dis Colon Rectum 1993;36:627-35.
19. Thynne GS, Weiland LH, Moertel CG, et al. Correlation of histopathologic characteristics of primary tumor and uninvolved regional lymph nodes in Dukes' C colonic carcinoma with prognosis. Mayo Clin Proc 1980;55:243-5.
20. Compton CC. Key issues in reporting common cancer specimens. Problems in pathologic staging of colon cancer. Arch Pathol Lab Med 2006;130:318-24.
21. LeVoyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912-9.
22. Wong JH, Steinemann S, Tom P, et al. Volume of lymphatic metastases does not independently influence prognosis in colorectal cancer. J Clin Oncol 2002;20:1506-11.
23. Bui L, Rempel E, Reeson D, et al. Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study. J Surg Oncol 2006;93:439-45.
24. Greenson JK, Isenhart CE, Rice R, et al. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer 1994;73:563-9.
25. Clarke G, Ryan E, O'Keane JC, et al. The detection of cytokeratins in lymph nodes of Duke's B colorectal cancer subjects predicts a poor outcome. Eur J Gastroenterol Hepatol 2000;12:549-52.
26. 0 colorectal cancer. Int J Colorectal Dis 2004;19:430-7.
27. Yasuda K, Adachi Y, Shiraishi N, et al. Pattern of lymph node micrometastasis and prognosis of patients with colorectal cancer. Ann Surg Oncol 2001;8:300-4.
28. Cutait R, Alves VAF, Lopes LC, et al. Restaging of colorectal cancer based on the identification of lymph node micrometastases through immunoperoxidase staining of CEA and cytokeratins. Dis Colon Rectum 1991;34:917-20.
29. Jeffers MD, O'Dowd GM, Mulcahy H, et al. The prognostic significance of immunohistochemically detected lymph node micrometastases in colorectal carcinoma. J Pathol 1994;172:183-7.
30. Adell G, Boeryd B, Franlund B, et al. Occurrence and prognostic importance of micrometastases in regional lymph nodes in Duke's B colorectal carcinoma: an immunohistochemical study. Eur J Surg 1996;162:637-42.
31. Choi H-J, Choi Y-Y, Hong S-H. Incidence and prognostic implications of isolated tumor cells in lymph nodes form patients with Duke's B colorectal carcinoma. Dis Colon Rectum 2002;45:750-6.
32. Fisher ER, Colangelo L, Wieand S, et al. Lack of influence of cytokeratin-positive mini micrometastases in "negative node" patients with colorectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Projects Protocols R-01and C-01. Dis Colon Rectum 2003;46:1021-6.
33. Zauber NP, Wang C, Lee PC, et al. Ki-ras gene mutations, LOH of the APC and DCC genes and micosatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. J Clin Pathol 2004;57:938-42.
34. Noura S, Yamamoto H, Miyake Y, et al. Immunohistochemical assessment of localization and frequency of micrometastases in lymph nodes of colorectal cancer. Clin Cancer Res 2002;8:759-67.
35. Turner RR, Nora DT, Trocha SD, et al. Colorectal carcinoma nodal staging. Frequency and nature of cytokeratin-positive cells in sentinel and nonsentinel lymph nodes. Arch Pathol Lab Med 2003;127:673-9.
36. Liefers G-J, Cleton-Jansen A-M, van de Velde CJH, et al. Micrometastases and survival in stage II colorectal carcinoma. N Engl J Med 1998;339:223-8.
37. Rosenberg R, Hoos A, Mueller J, et al. Impact of cytokeratin-20 and carcinoembryonic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer. Br J Cancer 2000;83:1323-9.
38. Noura S, Yamamoto H, Ohnishi T, et al. Comparative detection of lymph node micrometastases of stage II colorectal cancer by reverse transcriptase polymerase chain reaction and immunohistochemistry. J Clin Oncol 2002;20:4232-41.
39. 0) colorectal carcinoma: a meta-analysis. Ann Surg Oncol 2006;13:1386-92.
40. Bilchik A, Saha S, Wiese D, et al. Molecular staging of early colon cancer on the basis of sentinel node analysis: a multicenter phase II trial. J Clin Oncol 2001;19:1128-36.
41. Saha S, Bilchik A, Wiese D, et al. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique: a multicenter trial. Ann Surg Oncol 2001;8:94-8S.
42. Saha S, Seghal R, Patel M, et al. A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. Am J Surg 2006;191:305-10.
43. Baton O, Lasser P, Sabourin JC, et al. Ex vivo sentinel lymph node study for rectal adenocarcinoma: preliminary study. World J Surg 2005;29:1166-71.
44. Bembenek A, Schneider U, Gretschel S, et al. Detection of lymph node micrometastases and isolated tumor cells in sentinel and nonsentinel lymph nodes of colon cancer patients. World J Surg 2005;29:1172-5.
45. Redston M, Compton CC, Miedema BW, et al. Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer: results of Cancer and Leukemia Group B Trial 80001. J Clin Oncol 2006;24:878-83.
46. Martinez SR, Bilchik AJ. Quality control issues in the management of colon cancer patients. Eur J Surg Oncol 2005;31:616-29.
47. De Haas RJ, Wicherts DA, Hobbelink MG, et al. Sentinel lymph node mapping in colon cancer: current status. Ann Surg Oncol 2007;14:1070-80. Epub 2007 Jan 7.
48. Lindor NM, Burgart LJ, Leontovich O, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043-8.
49. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-8.
50. Lim SB, Jeong SY, Lee MR, et al. Prognostic significance of microsatellite instability in sporatic colorectal cancer. Int J Colorectal Dis 2004;19:533-7.
51. Greenson JK, Bonner JD, Ben-Yzhak O, et al. Phenotype of microsatellite unstable colorectal carcinomas. Am J Surg Pathol 2003;27:563-70.
52. Fridrichova I. New aspects in molecular diagnosis of Lynch syndrome (HNPCC). Cancer Biomarkers 2006;2:37-49.
53. Gologan A, Krasinskas A, Hunt J, et al. Performance of the revised Bethesda guidelines for identification of colorectal carcinomas with a high level of microsatellite instability. Arch Pathol Lab Med 2005;129:1390-7.
54. Munro AJ, Lain S, Lane DP. p53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434-44.
55. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006;24:5313-27.
56. Smyth EF, Sharma A, Sivarajasingham N, et al. Prognostic implications of hMLH1and p53 immunohistochemical status in right-sided colon cancer. Dis Colon Rectum 2004;17:2086-92.
57. Sinicrope FA, Rego RL, Halling KC, et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006;131:729-37.
58. Tornillo L, Lugli A, Zlobec I, et al. Prognostic value of cell cycle and apoptosis regulatory proteins in mismatch repair-proficient colorectal cancer. A tissue microarray-based approach. Am J Clin Pathol 2007;127:114-23.
59. Frederiksen CM, Knudsen S, Laurberg S, et al. Classification of Dukes' B and C colorectal cancers using expression arrays. J Cancer Res Clin Oncol 2003;129:263-71.
60. Kwon HC, Kim SH, Roh MS, et al. Gene expression profiling in lymph node-positive and lymph node-negative colorectal cancer. Dis Colon Rectum 2004;47:141-52.
61. Bianchini M, Levy E, Zucchini C, et al. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 2006;29:83-94.